Connect with us

Health

United States Officially Withdraws from World Health Organization After Year of Controversial Health Policy

Published

on

22 January 2026 was the United States’ final day as a member of the World Health Organization (WHO) after a year of polemic health policy decisions.

The withdrawal process began on 20 January 2025, when President Donald Trump signed an executive order to formally leave the international agency, concluding a year later as the United Nations formally acknowledged the departure. This marked Trump’s second attempt to exit the WHO, following a previous effort in 2020.

The U.S. government cited multiple reasons for leaving the WHO, including the organisation’s handling of the COVID-19 pandemic, its response to other global health crises, its failure to implement urgent reforms, and concerns about undue political influence from member states. Over the last decade, the United States contributed between $160 million and $815 million annually to the WHO, whose budget ranges from $2 billion to $3 billion.

Following the announcement, the Department of Health and Human Services, including the Centers for Disease Control and Prevention (CDC), imposed a government-wide communication pause. Agencies were prohibited from updating websites, releasing case numbers, issuing health advisories, posting on social media, and meeting with external partners. While limited communications resumed after a few weeks, U.S. health agencies remained largely disengaged from the WHO, affecting collaboration with international counterparts, including the European and African disease prevention centres.

The United States also declined to endorse the WHO’s legally binding Pandemic Agreement, signed in May 2025 in Geneva. The agreement aims to strengthen preparedness, prevent future pandemics, and ensure equitable access to medical supplies like vaccines. The Trump administration dissolved the Directorate of Global Health Security and Biodefense, which had coordinated pandemic response across U.S. agencies following the 2014-2015 Ebola outbreak.

See also  Is Eight Hours of Sleep Enough? Experts Weigh In on Sleep Quality and Health

Domestically, the U.S. shifted its public health guidance. In early 2026, Secretary of Health Robert F. Kennedy unveiled new dietary guidelines prioritising animal proteins such as red meat, poultry, seafood, and eggs, diverging from WHO recommendations that emphasise plant-based proteins. Vaccine recommendations were also reduced from 17 to 11, with immunisations for hepatitis A and B, influenza, meningococcal disease, and chickenpox removed from universal guidance. Officials cited Denmark, which recommends 10 vaccines, as a model, though critics warned against applying other countries’ policies without adaptation.

International aid was affected as well, with the closure of the U.S. Agency for International Development (USAID) after six decades of operation. In 2023, the United States provided $71.9 billion in foreign aid, including $16.1 billion for global health initiatives. A study in The Lancet warned that continued reductions could result in an additional 14.1 million deaths worldwide by 2030, including 4.5 million children under five.

The U.S. withdrawal marks a significant realignment of American health policy, distancing the country from multilateral health cooperation and raising concerns about the global response to future health emergencies.

Health

Genetic Differences May Shape Effectiveness of Popular Weight-Loss Drugs, Study Finds

Published

on

Genetic variations may help explain why some patients respond better than others to widely used weight-loss medications, according to new research that points to the potential for more personalised treatment approaches.

Drugs such as Ozempic, Mounjaro and Zepbound have transformed the treatment of obesity in recent years. These medications belong to a class known as GLP-1 receptor agonists, which mimic a natural hormone that regulates appetite and blood sugar, helping people feel full for longer. Despite their growing use, patient outcomes vary widely, with some individuals losing less than 5 percent of their body weight while others achieve reductions exceeding 20 percent.

The study, conducted by researchers at the 23andMe Research Institute and published in Nature, examined genetic data alongside patient-reported experiences to better understand these differences.

Researchers analysed information from nearly 28,000 participants who had taken GLP-1 medications for a median period of just over eight months. Their findings identified specific genetic variants that appear to influence how individuals respond to these treatments.

One such variation in the GLP1R gene was linked to improved effectiveness. Individuals carrying a particular version of this gene lost an average of 0.76 kilograms more than those without it during the study period. Another variant in the GIPR gene was associated with an increased likelihood of side effects such as nausea and vomiting among patients taking tirzepatide-based drugs, though it did not affect weight loss outcomes.

Noura Abul-Husn, chief medical officer at the research institute, said current approaches to weight management often rely on trial and error. She noted that patients frequently begin treatment without clear expectations about how effective a drug will be or what side effects they might experience.

See also  Albania Imposes New Rule to Retain Medical Graduates Amid Health Worker Shortage Crisis

Experts not involved in the study said the findings offer useful insight but should be interpreted with caution. Marie Spreckley of the University of Cambridge said the genetic effects identified are relatively small in clinical terms, especially compared with the typical weight loss of 10 to 15 percent seen in trials of these medications. She added that factors such as dosage, treatment duration, sex and drug type likely play a larger role in determining outcomes.

Still, researchers believe the results could mark a step toward more tailored therapies. Cristóbal Morales, a specialist in metabolic health in Spain, said the ability to predict how patients will respond to treatment through pharmacogenomics could improve both drug selection and safety.

The findings highlight the growing interest in personalised medicine, where treatments are adapted to an individual’s genetic profile, though further studies are needed to confirm how these insights can be applied in clinical practice.

Continue Reading

Health

Seven-Day Meditation Retreat Linked to Measurable Changes in Brain and Body, Study Finds

Published

on

A new study by researchers at the University of California San Diego suggests that a week of intensive meditation and mind-body practices may lead to measurable changes in both brain activity and physical health, highlighting a deeper connection between mental experience and biological function.

The findings, published in Communications Biology, indicate that consistent mental practices can activate biological pathways linked to brain flexibility, immune response, metabolism and natural pain relief. Researchers said the results point to a growing understanding that conscious experience and physical health are closely intertwined and may be used to improve overall well-being.

The study followed 20 healthy adults who participated in a seven-day residential retreat led by neuroscience educator Joe Dispenza. Participants completed about 33 hours of guided meditation along with lectures and group-based activities. Some elements were presented using an “open-label placebo” approach, meaning participants were aware that certain practices were described as placebos, yet previous research suggests such methods can still produce real effects through expectation and group dynamics.

To measure the impact of the retreat, researchers used functional MRI scans and blood tests before and after the programme. The results showed reduced activity in brain regions associated with constant internal thoughts, often described as mental “background noise,” suggesting more efficient brain function.

Blood samples also revealed changes linked to neuroplasticity, with lab-grown neurons exposed to post-retreat plasma showing increased growth and connectivity. Additional findings pointed to improved metabolic flexibility, as well as higher levels of endogenous opioids, the body’s natural painkillers.

Researchers also observed shifts in immune signalling, with both inflammatory and anti-inflammatory responses increasing in what they described as a more balanced and adaptive pattern. Participants reported stronger feelings of unity and altered awareness after the retreat, based on scores from a standard questionnaire used to assess such experiences.

See also  Drug Repurposing in Cancer Treatment: Emerging Strategies and Promising Developments

Hemal H. Patel, who was involved in the research, said the results go beyond simple stress reduction. He noted that combining multiple mind-body techniques appeared to influence several biological systems at once, with measurable effects in both brain scans and blood chemistry.

The study also found that patterns of brain connectivity observed after the retreat resembled those previously associated with psychedelic substances, suggesting that similar states may be achieved through meditation alone.

Despite the findings, researchers cautioned that the study was limited by its small sample size and lack of a control group. They said further research is needed to determine whether the same effects would be seen in larger and more diverse populations.

Alex Jinich-Diamant said the results provide rare biological evidence linking mental states to physical changes in the body. He added that the research offers new insight into how attention, belief and structured practices may leave measurable effects on human biology, opening potential pathways for improving health through non-pharmacological methods.

Continue Reading

Health

Uzbekistan to Launch Nationwide State Medical Insurance System in 2026

Published

on

Uzbekistan will begin introducing a nationwide state medical insurance system from 2026, part of a broader overhaul of the country’s healthcare financing and service delivery. The reform will introduce digital referrals, a national health insurance fund, and a guaranteed package of essential medical services funded through the state budget. Officials say the changes aim to improve efficiency, expand access, and reduce informal payments.

“State health insurance is a social protection system designed to guarantee access to quality healthcare services,” said Zokhid Ermatov, executive director of the State Health Insurance Fund.

Discussions about state medical insurance in Uzbekistan began in 2017, but implementing such a system required years of preparation. The State Health Insurance Fund was formally established in December 2020, and pilot programmes launched in the Syrdarya region in 2021 tested new financing mechanisms, regulatory frameworks, and digital health systems. In November 2025, the Cabinet of Ministers approved regulations governing how medical care funded through the state budget will be provided in public and private medical institutions, with the rules set to come into force on January 1, 2026.

At the centre of the new model is stronger primary healthcare. Patients will first visit their assigned family clinic, where doctors provide consultations, prescribe tests, and determine whether specialist care is needed. If necessary, patients will receive an electronic referral to hospitals or specialists. Emergency and urgent care will remain available without referrals.

The reform introduces a patient-centred financing model, where healthcare providers are paid by the State Health Insurance Fund based on services delivered. Primary healthcare will be funded through capitation payments, while hospital treatment will follow case-based payments, a structure designed to improve efficiency and treatment outcomes.

See also  Drug Repurposing in Cancer Treatment: Emerging Strategies and Promising Developments

A fully digital referral system will allow patients to choose hospitals from a list of institutions contracted with the State Health Insurance Fund using a government portal or mobile app. Referrals will remain valid for 60 days, and waiting lists and hospitalisations will be managed through a unified electronic health information system.

The insurance system guarantees essential healthcare services, including family doctor consultations, diagnostic tests, outpatient treatment, preventive screening, some medicines, hospital care, and certain rehabilitation services. Patients will not be charged additional fees for services included in the approved package.

Funding for the program will come primarily from the state budget, ensuring citizens do not pay direct insurance contributions. Priority access will be given to socially vulnerable groups, including children with disabilities, orphans, pensioners, pregnant women, unemployed citizens, and low-income families. The State Health Insurance Fund will allocate resources across regions to strengthen medical services and reduce inequalities.

International organisations have praised Uzbekistan’s approach, noting that general tax financing and universal coverage can improve financial protection and ensure predictable healthcare funding. Jessika Yin, Health Policy Adviser at the World Health Organization in Uzbekistan, said the reforms align with global trends toward universal health coverage.

If implemented successfully, Uzbekistan’s state medical insurance system could represent a major step toward universal healthcare, ensuring that people receive care without facing financial hardship.

Continue Reading

Trending